Use of Lactobacillus salivarius

Abstract

Lactobacillus salivarius is useful in the prophylaxis or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. The Lactobacillus salivarius is of human origin isolated from resected and washed human gastrointestinal tract. One such strain is UCC 118 described in WO-A-9835014.

1 . Use of a strain of  Lactobacillus salivarius  in the preparation of a medicament for the prophylaxis and/or treatment of undesirable inflammatory activity.  
     
     
         2 . Use as claimed in  claim 1  wherein the undesirable inflammatory activity is undesirable gastrointestinal inflammatory activity.  
     
     
         3 . Use as claimed in  claim 2  wherein the gastrointestinal inflammatory activity is inflammatory bowel disease.  
     
     
         4 . Use as claimed in  claim 3  wherein the gastrointestinal inflammatory activity is Crohns disease.  
     
     
         5 . Use as claimed in  claim 3  wherein the gastrointestinal activity is ulcerative colitis.  
     
     
         6 . Use as claimed in  claim 2  wherein the gastrointestinal inflammatory activity is irritable bowel syndrome.  
     
     
         7 . Use as claimed in  claim 2  wherein the gastrointestinal inflammatory activity is pouchitis.  
     
     
         8 . Use as claimed in  claim 2  wherein the gastrointestinal inflammatory activity is post infection colitis.  
     
     
         9 . Use as claimed in  claim 2  wherein the gastrointestinal inflammatory activity is diarrhoeal disease.  
     
     
         10 . Use as claimed in claimed  9  wherein the diarrhoel disease is associated by  Clostridium difficile.    
     
     
         11 . Use as claimed in  claim 9  wherein the diarrhoeal disease is associated with Rotovirus.  
     
     
         12 . Use as claimed in  claim 9  wherein the diarrhoeal disease is post infective diarrhoeal disease.  
     
     
         13 . Use as claimed in  claim 2  wherein the inflammatory activity is due to gastrointestinal cancer.  
     
     
         14 . Use as claimed in  claim 1  wherein the inflammatory activity is systemic inflammatory disease.  
     
     
         15 . Use as claimed in  claim 14  wherein the systemic inflammatory disease is rheumatoid arthritis.  
     
     
         16 . Use as claimed in  claim 1  or  2  wherein the undesirable inflammatory activity is due to an autoimmune disorder.  
     
     
         17 . Use as claimed in  claim 1  wherein the undesirable inflammatory activity is due to cancer.  
     
     
         18 . Use of a strain of  Lactobacillus salivarius  in the preparation of a medicament for the prophylaxis of cancer.  
     
     
         19 . Use as claimed in any of  claims 1  to  18  wherein the  Lactobacillus salivarius  is contained in a formulation.  
     
     
         20 . Use as claimed in  claim 19  wherein the formulation includes another prebiotic material.  
     
     
         21 . Use as claimed in  claim 19  or  20  wherein the formulation includes a prebiotic material.  
     
     
         22 . Use as claimed in any of  claims 19  to  21  wherein the formulation includes an ingestable carrier.  
     
     
         23 . Use as claimed in  claim 22  wherein the ingestable carrier is a pharmaceutically acceptable carrier such as a tablet, capsule or powder.  
     
     
         24 . Use as claimed in any of  claims 19  to  23  wherein the ingestable carrier is a protein and/or a peptide, in particular proteins and/or peptides that are rich in glutamine/glutamate; a lipid; a carbohydrate; a vitamin; mineral and/or trace element.  
     
     
         25 . Use as claimed in any of  claims 19  to  24  wherein the ingestable carrier is a food product such as acidified milk, yoghurt, frozen yoghurt, milk powder, milk concentrate, cheese spreads, dressings or beverages.  
     
     
         26 . Use as claimed in any of  claims 19  to  25  wherein the  Lactobacillus salivarius  is present at more than 10 6  cfu per gram of delivery system.  
     
     
         27 . Use as claimed in any of  claims 19  to  26  wherein the formulation includes an adjuvant.  
     
     
         28 . Use as claimed in any of  claims 19  to  27  wherein the formulation includes bacterial components.  
     
     
         29 . Use as claimed in any of  claims 19  to  28  wherein the formulation includes a drug entity.  
     
     
         30 . Use as claimed in any of  claims 19  to  29  wherein the formulation includes a biological compound.  
     
     
         31 . Use as claimed in any preceding claim wherein the strain or formulation is for administration to animals.  
     
     
         32 . Use as claimed in  claim 31  wherein the animal is a mammal.  
     
     
         33 . Use as claimed in  claim 32  wherein the mammal is a human.  
     
     
         34 . Use as claimed in any preceding claim wherein the  Lactobacillus salivarius  effects changes in an immunological marker when introduced into a system comprising cells which interact with the immune system and cells of the immune system.  
     
     
         35 . Use as claimed in  claim 34  wherein the cells which interact with the immune system are epithelial cells.  
     
     
         36 . Use as claimed in  claim 34  or  35  wherein the immunological marker is a cytokine.  
     
     
         37 . Use as claimed in  claim 36  wherein the cytokine is TNFα.  
     
     
         38 . Use as claimed in any of  claims 34  to  37  wherein the cells which interact with the immune system and the immure system cells are of matched origin.  
     
     
         39 . Use as claimed in any of  claims 34  to  38  wherein the cells which interact with the immune system are of gastrointestinal, respiratory or genitourinary origin.  
     
     
         40 . Use as claimed in any of  claims 34  to  39  wherein the cells of the immune system are of gastrointestinal, respiratory or genitourinary origin.  
     
     
         41 . Use as claimed in any preceding claim wherein the  Lactobacillus salivarius  strain is  Lactobacillus salivarius  subspecies  salivarius.    
     
     
         42 . Use as claimed in any preceding claim wherein the  Lactobacillus salivarius  is of human origin.  
     
     
         43 . Use as claimed in any preceding claim wherein the  Lactobacillus salivarius  is isolated from resected and washed human gastrointestinal tract.  
     
     
         44 . Use as claimed in any preceding claim wherein the  Lactobacillus salivarius  inhibits a broad range of Gram positive and Gram negative micro-organisms.  
     
     
         45 . Use as claimed in any preceding claim wherein  Lactobacillus salivarius  secretes a product having anti-microbial activity into a cell-free supernatant, said activity being produced only by growing cells and being destroyed by proteinase K and pronase E.  
     
     
         46 . Use as claimed in any preceding claim wherein the  Lactobacillus salivarius  strain is strain UCC 118 or a mutant or variant thereof.  
     
     
         47 . Use as claimed in any preceding claim wherein the  Lactobacillus salivarius  is a genetically modified mutant.  
     
     
         48 . Use as claimed in any preceding claim wherein the  Lactobacillus salivarius  is a naturally occurring variant of  Lactobacillus salivarius.    
     
     
         49 . Use as claimed in any preceding claim wherein the  Lactobacillus salivarius  is in the form of viable cells.  
     
     
         50 . Use as claimed in any preceding claims wherein the  Lactobacillus salivarius  is in the form of non-viable cells.